Langley, Richard G
1149  Ergebnisse:
Personensuche X
?
2

Bimekizumab 3-year Safety and Tolerability in Moderate to S..:

Lebwohl, Mark ; Strober, Bruce ; Langley, Richard G....
SKIN The Journal of Cutaneous Medicine.  8 (2024)  1 - p. s305 , 2024
 
?
3

Continuous Tralokinumab Treatment over 4 Years in Adults wi..:

Blauvelt, Andrew ; Langley, Richard G. ; Peris, Ketty...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  2 - p. s376 , 2024
 
?
 
?
6

Bimekizumab Continuous Maintenance of Eesponse at Every Vis..:

Blauvelt, Andrew ; Conrad, Curdin ; Costanzo, Antonio...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  1 - p. s303 , 2024
 
?
7

Bimekizumab Efficacy Through 3 Years in Patients with Moder..:

Lebwohl, Mark ; Strober, Bruce ; Foley, Peter...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  1 - p. s307 , 2024
 
?
9

Orismilast in moderate-to-severe psoriasis: Efficacy and sa..:

Warren, Richard B. ; French, Lars E. ; Blauvelt, Andrew...
Journal of the American Academy of Dermatology.  90 (2024)  3 - p. 494-503 , 2024
 
?
12

555 - Safety of tralokinumab for the treatment of atopic de..:

Reich, Kristian ; Langley, Richard G ; Silvestre, Juan Francisco...
British Journal of Dermatology.  190 (2024)  Supplement_2 - p. ii52-ii53 , 2024
 
?
13

551 - Continuous tralokinumab treatment over 4 years in adu..:

Blauvelt, Andrew ; Langley, Richard G ; Peris, Ketty...
British Journal of Dermatology.  190 (2024)  Supplement_2 - p. ii48-ii49 , 2024
 
?
15

43250 Efficacy of Apremilast in Patients With Moderate-to-S..:

Langley, Richard G. ; Mehta, Nehal N. ; Crowley, Jeffrey...
Journal of the American Academy of Dermatology.  89 (2023)  3 - p. AB158 , 2023
 
1-15